Creative Medical Technology Holdings, Inc. Proceeds from Convertible Debt
Creative Medical Technology Holdings, Inc. (CELZ) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2023-03-31
- Creative Medical Technology Holdings, Inc. proceeds from convertible debt for the quarter ending 2022-12-31 was $0.00.
- Creative Medical Technology Holdings, Inc. proceeds from convertible debt for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Creative Medical Technology Holdings, Inc. proceeds from convertible debt for the quarter ending 2022-06-30 was $0.00.
- Creative Medical Technology Holdings, Inc. proceeds from convertible debt for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Creative Medical Technology Holdings, Inc. proceeds from convertible debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Creative Medical Technology Holdings, Inc. proceeds from convertible debt for fiscal 2021 was $435.04K.
- Creative Medical Technology Holdings, Inc. proceeds from convertible debt for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Creative Medical Technology Holdings, Inc. proceeds from convertible debt for fiscal 2019 was $1.30M, a 27.82% decline from fiscal 2018.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 6 month as first filed | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 9 month as first filed | Proceeds from Convertible Debt 12 month | Proceeds from Convertible Debt 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 4 quarters · filed 2023-03-31 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $300.40K derived: sum of 4 quarters · filed 2023-03-31 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $300.40K derived: sum of 3 quarters · filed 2023-03-31 | $300.40K derived: sum of 4 quarters · filed 2023-03-31 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $300.40K derived: sum of 2 quarters · filed 2023-03-31 | $300.40K derived: sum of 3 quarters · filed 2023-03-31 | $435.04K 10-K · filed 2023-03-31 | $3.89M 10-K · filed 2022-03-30 | ||
| 2021-09-30 | $300.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $300.40K derived: sum of 2 quarters · filed 2022-11-10 | $435.04K 10-Q · filed 2022-11-10 | $3.89M 10-Q · filed 2021-11-15 | $435.04K derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $134.64K 10-Q · filed 2022-08-12 | $100.00K 10-Q · filed 2021-08-16 | $134.64K derived: sum of 3 quarters · filed 2022-08-12 | $134.64K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2021-03-31 | $134.64K 10-Q · filed 2022-05-13 | $134.64K derived: sum of 2 quarters · filed 2022-05-13 | $134.64K derived: sum of 3 quarters · filed 2022-05-13 | -$10.36K derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | -$145.00K derived: sum of 3 quarters · filed 2022-03-30 | $0.00 10-K · filed 2022-03-30 | $710.92K 10-K · filed 2021-03-17 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$145.00K derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | $458.60K 10-Q · filed 2020-11-13 | $255.50K derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | -$145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $0.00 10-Q · filed 2021-08-16 | $275.20K 10-Q · filed 2020-08-14 | $255.50K derived: sum of 3 quarters · filed 2021-08-16 | $612.90K derived: sum of 4 quarters · filed 2021-08-16 | ||
| 2020-03-31 | $145.00K 10-Q · filed 2021-05-17 | $400.50K derived: sum of 2 quarters · filed 2021-05-17 | $757.90K derived: sum of 3 quarters · filed 2021-05-17 | $871.90K derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $255.50K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $612.90K derived: sum of 2 quarters · filed 2021-03-17 | $726.90K derived: sum of 3 quarters · filed 2021-03-17 | $1.30M 10-K · filed 2021-03-17 | |||
| 2019-09-30 | $357.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $471.40K derived: sum of 2 quarters · filed 2020-11-13 | $1.05M 10-Q · filed 2020-11-13 | $1.47M derived: sum of 4 quarters · filed 2020-11-13 | |||
| 2019-06-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $689.89K 10-Q · filed 2020-08-14 | $1.12M derived: sum of 3 quarters · filed 2020-08-14 | $1.75M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | $575.89K 10-Q · filed 2020-05-15 | $1.00M derived: sum of 2 quarters · filed 2020-05-15 | $1.64M derived: sum of 3 quarters · filed 2020-05-15 | $2.13M derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | $426.86K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-06 | $1.06M derived: sum of 2 quarters · filed 2020-04-06 | $1.55M derived: sum of 3 quarters · filed 2020-04-06 | $1.80M 10-K · filed 2020-04-06 | |||
| 2018-09-30 | $634.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $1.12M derived: sum of 2 quarters · filed 2019-11-14 | $1.38M 10-Q · filed 2019-11-14 | $1.49M derived: sum of 4 quarters · filed 2019-11-14 | |||
| 2018-06-30 | $488.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $743.31K 10-Q · filed 2019-08-13 | $850.31K derived: sum of 3 quarters · filed 2019-08-13 | $940.81K derived: sum of 4 quarters · filed 2019-08-13 | |||
| 2018-03-31 | $254.35K 10-Q · filed 2019-05-20 | $361.35K derived: sum of 2 quarters · filed 2019-05-20 | $451.85K derived: sum of 3 quarters · filed 2019-05-20 | $737.60K derived: sum of 4 quarters · filed 2019-05-20 | |||
| 2017-12-31 | $107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $197.50K derived: sum of 2 quarters · filed 2019-04-01 | $483.25K derived: sum of 3 quarters · filed 2019-04-01 | $483.25K 10-K · filed 2019-04-01 | |||
| 2017-09-30 | $90.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $376.25K derived: sum of 2 quarters · filed 2018-11-14 | $376.25K 10-Q · filed 2018-11-14 | $376.25K derived: sum of 4 quarters · filed 2018-11-14 | |||
| 2017-06-30 | $285.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $285.75K 10-Q · filed 2018-08-14 | $285.75K derived: sum of 3 quarters · filed 2018-08-14 | $285.75K derived: sum of 4 quarters · filed 2018-08-14 | |||
| 2017-03-31 | $0.00 10-Q · filed 2018-08-03 | $0.00 derived: sum of 2 quarters · filed 2018-08-03 | $0.00 derived: sum of 3 quarters · filed 2018-08-03 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $0.00 derived: sum of 2 quarters · filed 2018-03-29 | $0.00 10-K · filed 2018-03-29 | ||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $0.00 10-Q · filed 2017-11-13 | |||||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |